Who are Heron Therapeutics, Inc.'s main suppliers?

Heron Therapeutics, Inc. (HRTX) key suppliers include: Cumberland Pharmaceuticals Inc., Cumberland Pharmaceuticals Inc., Merck & Co., Inc., Merck & Co., Inc., ORANY and 5 more. View the full supplier network at chainsifter.com/chain/HRTX.

Who are Heron Therapeutics, Inc.'s major customers?

Heron Therapeutics, Inc. (HRTX) key customers include: Cumberland Pharmaceuticals Inc., Cumberland Pharmaceuticals Inc., Hercules Capital, Inc., Hercules Capital, Inc., Merck & Co., Inc. and 13 more. View the full customer network at chainsifter.com/chain/HRTX.

What sector is Heron Therapeutics, Inc. in?

Heron Therapeutics, Inc. (HRTX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Heron Therapeutics, Inc. Suppliers, Customers & Supply Chain (HRTX)

10Suppliers

18Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Heron Therapeutics, Inc. (HRTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

32Total relationships

4Distinct source URLs

4High confidence

0.718Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Heron Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CPIX	Cumberland Pharmaceuticals Inc.	72%	omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin…
CPIX	Cumberland Pharmaceuticals Inc.	72%	Reciprocal relationship from CPIX graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from CPIX graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, …
MRK	Merck & Co., Inc.	72%	omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from ORAN…
ORANY	ORANY	72%	that we have effective internal control over our financial reporting, investors could lose confidence in the reliability of our financial statements. Failure to comply with reporting requirements cou…
PCRX	Pacira BioSciences, Inc.	72%	omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin…
PCRX	Pacira BioSciences, Inc.	72%	Reciprocal relationship from PCRX graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological …
TKPHF	Takeda Pharmaceutical Company Limited	72%	Reciprocal relationship from TKPHF graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from TKPH…
TKPHF	Takeda Pharmaceutical Company Limited	72%	omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin…

Heron Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
CPIX	Cumberland Pharmaceuticals Inc.	72%	omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin…
CPIX	Cumberland Pharmaceuticals Inc.	72%	Reciprocal relationship from CPIX graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological …
HTGC	Hercules Capital, Inc.	72%	Reciprocal relationship from HTGC graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from HRTX graph: to register for resale 12.4 million…
HTGC	Hercules Capital, Inc.	72%	to register for resale 12.4 million shares of our common stock underlying the Senior Convertible Notes, including the maximum number of shares of common stock issuable under the make-whole premium. T…
MRK	Merck & Co., Inc.	72%	omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological a…
PCRX	Pacira BioSciences, Inc.	72%	omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin…
PCRX	Pacira BioSciences, Inc.	72%	Reciprocal relationship from PCRX graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological …
TKPHF	Takeda Pharmaceutical Company Limited	72%	Reciprocal relationship from TKPHF graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from TKPH…
TKPHF	Takeda Pharmaceutical Company Limited	72%	omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin…
AZURITY-PHARMACEUTICALS-INC	AZURITY-PHARMACEUTICALS-INC	62%	e comparable period in 2025. The increase was primarily attributable to an increase in the units sold as a result of an increase in market share and new customers for both ZYNRELEF and APONVIE. Total…
BAX	Baxter International Inc.	62%	Reciprocal relationship from BAX graph: Reciprocal relationship from HRTX graph: e comparable period in 2025. The increase was primarily attributable to an increase in the units sold as a result of a…
BAXTER-HEALTHCARE-CORPORATION	BAXTER-HEALTHCARE-CORPORATION	62%	e comparable period in 2025. The increase was primarily attributable to an increase in the units sold as a result of an increase in market share and new customers for both ZYNRELEF and APONVIE. Total…
FRESENIUS-KABI-USA-LLC	FRESENIUS-KABI-USA-LLC	62%	ntial risks and needs for additional manufacturers and other suppliers for the manufacturing of our Products. Establishing additional or replacement suppliers for certain raw materials in our proprie…
INNOCOLL-PHARMACEUTICALS-LIMITED	INNOCOLL-PHARMACEUTICALS-LIMITED	62%	ntial risks and needs for additional manufacturers and other suppliers for the manufacturing of our Products. Establishing additional or replacement suppliers for certain raw materials in our proprie…
MYLAN-PHARMACEUTICALS-INC	MYLAN-PHARMACEUTICALS-INC	62%	e comparable period in 2025. The increase was primarily attributable to an increase in the units sold as a result of an increase in market share and new customers for both ZYNRELEF and APONVIE. Total…
QILU-PHARMA-INC	QILU-PHARMA-INC	62%	e comparable period in 2025. The increase was primarily attributable to an increase in the units sold as a result of an increase in market share and new customers for both ZYNRELEF and APONVIE. Total…
SLAYBACK-PHARMA-LLC	SLAYBACK-PHARMA-LLC	62%	e comparable period in 2025. The increase was primarily attributable to an increase in the units sold as a result of an increase in market share and new customers for both ZYNRELEF and APONVIE. Total…

Heron Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
HRTX-DEBT-10080	Warrants outstanding: 220164	90%	xbrl warrant detail from xbrl 2023-12-31.
HRTX-DEBT	Debt stack $141.6M	90%	Market cache reports total debt of $141.6M.
HRTX-DEBT-10081	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2026-03-31.

Heron Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Heron Therapeutics, Inc..

Heron Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
HRTX-OWNER-RUBRIC-CAPITAL-MANAGEMENT-LP	Rubric Capital Management LP	90%	13F overlay lists Rubric Capital Management LP as top holder; 169 tracked holders.

Heron Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CTMX	CytomX Therapeutics, Inc.	100.00	2
ALEC	Alector, Inc.	100.00	2
BCYC	Bicycle Therapeutics plc	100.00	2
ALT	Altimmune, Inc.	100.00	2
CPIX	Cumberland Pharmaceuticals Inc.	100.00	1	['customer', 'supplier']
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
BAX	Baxter International Inc.	100.00	1	['customer']
EDSA	Edesa Biotech, Inc.	100.00	2
HTGC	Hercules Capital, Inc.	100.00	1	['customer']
IRON	Disc Medicine, Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2
ORANY	ORANGE	100.00	1	['supplier']
SDGR	Schrödinger, Inc.	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
CMPS	COMPASS Pathways plc	100.00	2

Heron Therapeutics, Inc. Supply Chain